{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "a2832c98-62b0-4b7f-8c1b-adb8e2570344",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[Truncated to first 65536 bytes]\n"
     ]
    },
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "'\"Id\\tStudy Title\\tAcronym\\tStatus\\tConditions\\tInterventions\\tSponsor\\tCollaborators\\tEnrollment\\tFunder Type\\tType\\tStudy Design\\tStart\\tCompletion\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03630471\\tEffectiveness of a Problem-solving Intervention for Common Adolescent Mental Health Problems in India\\tPRIDE\\tCOMPLETED\\tMental Health Issue (E.G.\", Depression, Psychosis, Personality Disorder,\" Substance Abuse)\\tBEHAVIORAL: PRIDE \\'Step 1\\' problem-solving intervention|BEHAVIORAL: Enhanced usual care\\tSangath\\tHarvard Medical School (HMS and HSDM)|London School of Hygiene and Tropical Medicine\\t250.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2018-08-20\\t2019-02-28\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05992571\\tOral Ketone Monoester Supplementation and Resting-state Brain Connectivity\\t\\tRECRUITING\\tCerebrovascular Function|Cognition\\tOTHER: Placebo|DIETARY_SUPPLEMENT: β-OHB\\tMcMaster University\\tAlzheimer\\'s Society of Brant\", Haldimand Norfolk,\" Hamilton Halton\\t30.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE\\t2023-10-25\\t2024-08\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00237471\\tImpact of Tight Glycaemic Control in Acute Myocardial Infarction\\t\\tTERMINATED\\tMyocardial Infarct|Hyperglycemia\\tDRUG: Insulin (tight blood glucose control)\\tMelbourne Health\\tNational Health and Medical Research Council\",\" Australia|Bristol-Myers Squibb\\t40.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2005-10\\t2006-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03820271\\tNew Prognostic Predictive Models of Mortality of Decompensated Cirrhotic Patients Waiting for Liver Transplantation\\tSUPERMELD\\tRECRUITING\\tDecompensated Cirrhosis|Liver Transplantation\\tOTHER: SuperMELD\\tAssistance Publique - Hôpitaux de Paris\\t\\t500.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER\\t2020-10-01\\t2023-10-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT06229171\\tInTake Care: Development and Validation of an Innovative\",\" Personalized Digital Health Solution for Medication Adherence Support in Cardiovascular Prevention\\tInTakeCare\\tNOT_YET_RECRUITING\\tHypertension|Treatment Adherence and Compliance|Digital Health\\tOTHER: adherence support system based on a vocal assistant\\tIstituto Auxologico Italiano\\tIstituti Clinici Scientifici Maugeri SpA|Politecnico di Milano\\t206.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER\\t2024-10-01\\t2026-04-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02945371\\tTailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life\\tREV\\tCOMPLETED\\tSmoking|Alcohol Drinking|Prescription Drug Abuse|Substance-Related Disorders|Oral Intake Reduced\\tBEHAVIORAL: Person-centered inhibitory control training|BEHAVIORAL: Active behavioral response training\\tUniversity of Oregon\\t\\t103.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION\\t2014-09\\t2016-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01055171\\tNeuromodulation of Trauma Memories in PTSD & Alcohol Dependence\\t\\tCOMPLETED\\tAlcohol Dependence|PTSD\\tDRUG: Propranolol|DRUG: Placebo\\tMedical University of South Carolina\\tNational Institute on Alcohol Abuse and Alcoholism (NIAAA)\\t44.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2010-01\\t2012-08\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01125371\\tComputerized Brief Alcohol Intervention (BI) for Binge Drinking HIV At-Risk and Infected Women\\t\\tCOMPLETED\\tAlcohol; Harmful Use|Binge Drinking|Risk Behavior|HIV Infection\\tBEHAVIORAL: Computerized brief alcohol intervention + IVR booster calls|BEHAVIORAL: Computerized brief alcohol intervention|BEHAVIORAL: Attention Control\\tJohns Hopkins University\\tNational Institute on Alcohol Abuse and Alcoholism (NIAAA)\\t439.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2011-10\\t2016-06-07\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02554071\\tManitoba Pharmacist Initiated Smoking Cessation Pilot Project\\t\\tCOMPLETED\\tSmoking Cessation\\tOTHER: Pharmacist - Smoking Cessation Support\\tUniversity of Manitoba\\tGovenment of Manitoba|Canadian Foundation for Pharmacy|Neighbourhood Pharmacy Association of Canada\\t119.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE\\t2014-01\\t2014-11\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01772771\\tMolecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program\\t\\tRECRUITING\\tGlioma|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Melanoma|Sarcoma\\tPROCEDURE: Biospecimen Collection|OTHER: Genetic Testing|OTHER: Medical Chart Review\\tM.D. Anderson Cancer Center\\tNational Cancer Institute (NCI)\\t12000.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2012-03-01\\t2033-03-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02633371\\tA Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults\\t\\tCOMPLETED\\tHyperhidrosis\\tDRUG: Oxybutynin 3% gel\\tUniversity of Colorado\",\" Denver\\tSociety for Pediatric Dermatology\\t10.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2016-02\\t2017-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03400371\\tBiology of Juvenile Myoclonic Epilepsy\\tBIOJUME\\tRECRUITING\\tJuvenile Myoclonic Epilepsy\\tOTHER: Blood draw|OTHER: Existing samples\\tKing\\'s College London\\tKing\\'s College Hospital NHS Trust|Charles University\",\" Czech Republic|Hopital Universitaire Robert-Debre|Vestre Viken Hospital Trust|The Hospital for Sick Children|Cardiff University|Odense University Hospital\\t1000.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2017-07-13\\t2026-06-30\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00120471\\tSafety and Blood Levels of Tenofovir Disoproxil Fumarate in HIV Infected Pregnant Women and Their Babies\\t\\tCOMPLETED\\tHIV Infections\\tDRUG: Tenofovir disoproxil fumarate|DRUG: Tenofovir disoproxil fumarate|DRUG: Tenofovir disoproxil fumarate\\tNational Institute of Allergy and Infectious Diseases (NIAID)\\tEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)\\t122.0\\tNIH\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION\\t2006-11\\t2011-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04784871\\tPromoting Wellbeing: The Five Ways to All Intervention\\t5WaysA\\tCOMPLETED\\tWellbeing|Health Attitude|Quality of Life\\tBEHAVIORAL: 5waysA Intervention|BEHAVIORAL: 5waysA Active wait-list control|BEHAVIORAL: 5waysA Inactive wait-list control\\tUniversity of Oslo\\tNorwegian Institute of Public Health|Norwegian Council for Mental Health|The Dam Foundation\\t970.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION\\t2021-03-04\\t2023-02-24\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02383771\\tReversal of the Anti-platelet Effects of Ticagrelor\\tREVERSAL\\tCOMPLETED\\tCoronary Artery Disease\\tDRUG: Ticagrelor|DRUG: Aspirin + Ticagrelor|DRUG: Control|DRUG: Aspirin + Ticagrelor\\tThe First Affiliated Hospital with Nanjing Medical University\\tNational Natural Science Foundation of China\\t64.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT\\t2015-03\\t2016-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03269071\\tNeural Stem Cell Transplantation in Multiple Sclerosis Patients\\tSTEMS\\tCOMPLETED\\tProgressive Multiple Sclerosis\\tDRUG: human fetal-derived Neural Stem Cells (hNSCs)\\tIRCCS San Raffaele\\tFondazione Italiana Sclerosi Multipla\\t4.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT\\t2017-05-17\\t2021-07-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01659671\\tRCT of the Effect of Uvulopalatopharyngoplasty Compared to Expectancy in Patients With Obstructive Sleep Apnea\\tSKUP3\\tCOMPLETED\\tObstructive Sleep Apnea Syndrome\\tPROCEDURE: Uvulopalatopharyngoplasty\\tKarolinska University Hospital\\tKarolinska Institutet\\t65.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2007-06\\t2014-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04765371\\tComparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy\",\" With CoViD-19\\tCOPreDex\\tCOMPLETED\\tCoronavirus Infection\\tDRUG: DEXAMETHASONE|DRUG: PREDNISOLONE\\tHôpital NOVO\\t\\t89.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2021-03-03\\t2022-05-13\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02830971\\tDeveloping a Standardized Learning Curve\\t\\tCOMPLETED\\tRegistered Nurses|Nursing Personnel|Motor Skills\\tPROCEDURE: Doing Different ICU techniques and skills\\tBaqiyatallah Medical Sciences University\\tShahid Beheshti University|Tehran University of Medical Sciences\\t60.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE\\t2016-07\\t2021-04-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00416871\\tInterleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer\\t\\tCOMPLETED\\tKidney Cancer\\tBIOLOGICAL: aldesleukin|BIOLOGICAL: recombinant interferon alfa\\tCentre Leon Berard\\t\\t220.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: |Masking: NONE|Primary Purpose: TREATMENT\\t\\t2006-02\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05900271\\tDutch-Depression Outcome Trial Comparing 5 Day Multi Daily Neuronavigated Theta Burst Sessions With 6 Weeks rTMS\\tDDOT\\tACTIVE_NOT_RECRUITING\\tTreatment Resistant Depression\\tDEVICE: rTMS|DEVICE: iTBS\\tAmsterdam UMC\",\" location VUmc\\tRadboud University Medical Center|University Medical Center Groningen|Maastricht University|Trimbos|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)\\t108.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2023-11-15\\t2027-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02469571\\tModulation of Gut Microbiota in Early Sepsis: A Pilot Study\\tMGM-sepsis\\tCOMPLETED\\tSepsis\\tDIETARY_SUPPLEMENT: Winclove 607|DIETARY_SUPPLEMENT: Placebo\\tMedical University of Graz\\t\\t15.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION\\t2015-09-01\\t2018-03-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05807971\\tAssessment of Safety\", Tolerability, Pharmacokinetics,\" and Pharmacodynamics of ATH-063 in Healthy Subjects\\t\\tRECRUITING\\tInflammatory Bowel Diseases|Crohn Disease|Ulcerative Colitis|Autoimmune Diseases\\tDRUG: ATH-063|DRUG: Placebo\\tAthos Therapeutics Inc\\tSyneos Health|Athos Therapeutics Australia Pty Ltd\\t76.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2023-04-06\\t2024-02-08\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02083471\\tCow\\'s Milk and Hen\\'s Egg Hyposensitization in Adults\\t\\tUNKNOWN\\tEgg Allergy|Cow\\'s Milk Allergy\\tDIETARY_SUPPLEMENT: Specific Oral Tolerance Induction with Egg or Cow\\'s milk\\tTurku University Hospital\\t\\t40.0\\tOTHER_GOV\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2015-04\\t2017-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01062971\\tClinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide\\t\\tCOMPLETED\\tPrimary Open Angle Glaucoma|Ocular Hypertension\\tDRUG: dorzolamide-timolol-brimonidine\\tLaboratorios Sophia S.A de C.V.\\t\\t124.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT\\t2006-02\\t2008-06\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03928171\\tThe Effect of Intra-abdominal Pressure on Peritoneal Perfusion During Laparoscopic Colorectal Surgery\\tPERFUSION\\tCOMPLETED\\tLaparoscopic Surgery|Pneumoperitoneum\\tOTHER: Intra-abdominal pressure during laparoscopy\\tRadboud University Medical Center\\t\\t30.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2018-06-13\\t2018-12-24\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00897871\\tEvaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer\\t\\tUNKNOWN\\tUnspecified Childhood Solid Tumor\",\" Protocol Specific\\tDRUG: carboplatin|DRUG: cyclophosphamide|DRUG: etoposide phosphate|GENETIC: gene expression analysis|GENETIC: polymorphism analysis|OTHER: pharmacological study\\tChildren\\'s Cancer and Leukaemia Group\\t\\t60.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2007-02\\t\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00848471\\tValidation of the Quark RMR Calorimeter (Cosmed) Versus Deltatrac II (GE Health Care Clinical Systems)\\tProtocol Quark\\tUNKNOWN\\tHealthy|Obesity\\tDEVICE: Quark RMR|DEVICE: Deltatrac II\\tHospices Civils de Lyon\\tCentre de Recherche en Nutrition Humaine Rhone-Alpe\\t30.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH\\t2009-01\\t2009-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT06135571\\tStudy on the No.253 Lymph Node Metastasis Patterns in Left-Sided Colon and Rectal Cancer\\t\\tRECRUITING\\tColorectal Cancer|Lymph Node Metastasis\\tPROCEDURE: Laparoscopic colorectal surgery\\tCancer Institute and Hospital\",\" Chinese Academy of Medical Sciences\\tPeking Union Medical College Hospital|Peking University Cancer Hospital & Institute|China-Japan Friendship Hospital|Chinese PLA General Hospital\\t3000.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2023-09-01\\t2026-09-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01189071\\tPreoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain\\t\\tTERMINATED\\tOveractive Bladder|Renal Colic|Pain\",\" Postoperative\\tDRUG: Darifenacin\\tUniversity of Missouri-Columbia\\t\\t3.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT\\t2009-08\\t2011-07\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00728871\\tThe Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis\\t\\tUNKNOWN\\tCervical Cancer|Cervical Intraepithelial Neoplasia\\tPROCEDURE: peripheral blood isolation\\tNational Taiwan University Hospital\\t\\t600.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE\\t2005-12\\t2011-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05592171\\tOcclusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC\\tSEASON-HCC\\tRECRUITING\\tHCC\\tPROCEDURE: Microwave ablation + Occlusafe + DEB-TACE|PROCEDURE: Microwave ablation + Occlusafe|PROCEDURE: Microwave ablation + DEB-TACE\\tUniversity of Pisa\\tAzienda Ospedaliera Città della Salute e della Scienza di Torino|Fondazione Policlinico Universitario Agostino Gemelli IRCCS|Azienda Ospedaliera Universitaria Policlinico|IRCCS Azienda Ospedaliero-Universitaria di Bologna|Terumo Europe N.V.|Azienda Ospedaliero\",\" Universitaria Pisana\\t60.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2022-10-17\\t2025-10-17\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00520871\\tThe Water-Blueberry Study\\t\\tCOMPLETED\\tCardiovascular Disease\\tDRUG: Blueberry juice\\tUniversity of Oslo\\tUllevaal University Hospital\\t62.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: PREVENTION\\t2003-03\\t2004-04\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05913271\\tStudy on the Correlation Between NAT2(N-acetyltransferase2) Gene Polymorphism and CrCl(Creatine Clreance) and the Efficacy and Safety of Levosimendan in Patients With Severe Heart Failure\\t\\tRECRUITING\\tHeart Failure|Levosimendan|Efficacy|Safety\\t\\tYi Han\\tQianfoshan Hospital\\t352.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2023-05-30\\t2025-05-30\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04006171\\tComparison of Serum C Type Natriuretic Peptide Levels Between Polycystic Ovary Syndrome Patients and Healthy Women\\tCNP\\tCOMPLETED\\tPolycystic Ovary Syndrome|c Type Natriuretic Peptide|Menstrual Irregularity|Hyperandrogenism\\tDIAGNOSTIC_TEST: C type natriuretic peptide\\tNear East University\",\" Turkey\\t\\t90.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC\\t2019-07-15\\t2020-09-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04370171\\tManagement of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic\\tTeleCoviDiab\\tCOMPLETED\\tDiabetes|Covid-19\\tOTHER: care modalities|OTHER: Teleconsultation either by phone or by computer consultation\\tUniversity Hospital\", Strasbourg,\" France\\t\\t610.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2020-05-04\\t2020-05-29\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04340271\\tThe Clinical Utility of Extracorporeal Shock Wave Therapy on Burns\\t\\tCOMPLETED\\tBurn Scar\\tOTHER: Extracorporeal shock wave therapy|OTHER: conventional occupational therapy\\tHangang Sacred Heart Hospital\\t\\t48.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2020-04-15\\t2020-05-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03075371\\tHomeostatic and Non-homeostatic Processing of Food Cues in Anorexia Nervosa\\t\\tCOMPLETED\\tAnorexia Nervosa|Healthy\\tOTHER: Glucose|OTHER: Placebo\\tUniversity of Heidelberg Medical Center\\tGerman Research Foundation\\t85.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE\\t2014-09\\t2019-02\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05966571\\tOvarian Innervation Study in Patients With Polycystic Ovary Syndrome (PCOS)\\t\\tRECRUITING\\tPolycystic Ovary Syndrome\\tPROCEDURE: Ovary Biopsie\\tAlbanian University\\t\\t50.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2023-07-01\\t2024-12-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03313271\\tChina Lymphoma Patient Registry Study\\tCLAP\\tRECRUITING\\tLymphoma\\t\\tJun Zhu\\tPeking University First Hospital|Tianjin Medical University Cancer Hospital|Zhejiang Cancer Hospital|Heilongjiang Cancer Hospital|Sipai(Beijing)Network Technology Co Ltd\\t5000.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2017-05-17\\t2027-08-30\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03490071\\tLong-term Follow up of Patients With Longstanding Hip and Groin Pain\\tLund LHGP\\tRECRUITING\\tHip Pain Chronic\\t\\tLund University\\t\\t81.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2018-01-01\\t2024-12-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05801471\\tClinical Evaluation of Visual Field Change in Glaucoma: an Assessment of Different Models of Progression\\t\\tRECRUITING\\tGlaucoma\\t\\tCentervue SpA\\t\\t200.0\\tINDUSTRY\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2022-05-06\\t2025-11-06\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00266071\\tStudy of the Cutaneous Microcirculation in Elderly People\\t\\tUNKNOWN\\tElderly People\\tBEHAVIORAL: Cutaneous response\\tUniversity Hospital\",\" Angers\\t\\t\\tOTHER_GOV\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2005-12\\t\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04405271\\tTAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)\\t\\tUNKNOWN\\tHealthcare Workers|COVID-19|SARS-CoV 2\\tDRUG: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|DRUG: Placebo\\tHospital Italiano de Buenos Aires\\tSociedad Argentina de Infectología (SADI) (Argentine Society of Infectious Diseases)\\t1378.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION\\t2020-07-31\\t2020-11-15\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02121171\\tCombined Trab+Trab Versus Combined Trab+Trab With Subconjunctival Implantation of Ologen for Primary Congenital Glaucoma\\t\\tUNKNOWN\\tCongenital Glaucoma\\tDEVICE: Ologen Collagen Matrix|PROCEDURE: Combined trabeculotomy-trabeculectomy\\tNational Centre of Ophthalmology named after academician Zarifa Aliyeva\\tAeon Astron Europe B.V.\\t40.0\\tOTHER_GOV\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2010-09\\t2015-09\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01068171\\tDeveloping a Diabetic Foot Ulcer Protocol\\t\\tWITHDRAWN\\tDiabetic Foot Ulcers\\tOTHER: type of footwear|OTHER: collagen dressing with and without silver\\tThe University of Texas Health Science Center\",\" Houston\\tHarris County Hospital District|Baylor College of Medicine\\t0.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2010-05\\t2012-06\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04875871\\tParticle-based Partial Tumor Irradiation of Unresectable Bulky Tumors\\tPARTICLE-PATHY\\tRECRUITING\\tCancer\\tRADIATION: Particle radiotherapy|DIAGNOSTIC_TEST: Magnetic resonance imaging|DIAGNOSTIC_TEST: Computertomography|DIAGNOSTIC_TEST: Copper-64-Diacetyl-bis (N4-methylthiosemicarbazone) Positron Emission Tomography-Computer Tomography (64Cu-ATSM-PET-CT)|DIAGNOSTIC_TEST: 18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)|DIAGNOSTIC_TEST: Blood sampling\\tEBG MedAustron GmbH\\tCW-Research & Management GmbH|Medical University of Vienna|Landesklinkum Wiener Neustadt|Klinik Ottakring\\t22.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2021-11-11\\t2024-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00553371\\tFollow-up Evaluation Using CT Scans in Patients Who Have Been Treated For Metastatic Testicular Cancer\\t\\tUNKNOWN\\tTesticular Germ Cell Tumor\\tOTHER: biomarker analysis|PROCEDURE: computed tomography\\tRoyal Marsden NHS Foundation Trust\\t\\t300.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2006-04\\t\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04674371\\tGerman Point Prevalence Study on CVC\\t\\tCOMPLETED\\tData Collection\\tOTHER: central venous catheter insertion\\tWolfram Schummer\", MD,\" PhD\\t\\t537.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2022-05-17\\t2022-05-20\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02321371\\tEffect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy.\\t\\tCOMPLETED\\tAcute-On-Chronic Liver Failure\\tDRUG: Lactulose + Rifaximin|DRUG: Lactulose\\tInstitute of Liver and Biliary Sciences\",\" India\\t\\t73.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2014-10-19\\t2016-01-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02344771\\tPerioperative Endothelial Dysfunction\\t\\tCOMPLETED\\tMyocardial Injury\\tPROCEDURE: Elective colon cancer surgery\\tZealand University Hospital\\t\\t31.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2015-03\\t2015-06\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03354871\\tDeveloping Models for Fatigue Monitoring in Obstetrics and Gyne- Cology Residents Using Wearables\\tIoT4Resident\\tUNKNOWN\\tFatigue\\t\\tHillel Yaffe Medical Center\\tInternational Business Machines (IBM)\\t6.0\\tOTHER_GOV\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2017-11\\t2018-02-28\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02804971\\tCardiovascular Comorbidities and Bronchiectasis\\tBRONCOCA\\tACTIVE_NOT_RECRUITING\\tBronchiectasis\\t\\tCentre Hospitalier Intercommunal Creteil\\t\\t200.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2016-10-25\\t2023-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04591171\\tAssessing the Feasibility of N-of-1 Trials in Children With Hypertension and Chronic Kidney Disease\\t\\tCOMPLETED\\tHypertension|Chronic Kidney Diseases\\tPROCEDURE: n-of-1 trial guided clinical decision making\\tThe University of Texas Health Science Center\",\" Houston\\tChildren\\'s Hospital of Philadelphia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\\t9.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2021-01-25\\t2022-02-18\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04814771\\tMass Balance Study of TS-142 in Healthy Adult Subjects.\\t\\tCOMPLETED\\tHealthy Male Subjects\\tDRUG: [14C] TS-142\\tTaisho Pharmaceutical Co.\",\" Ltd.\\t\\t6.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE\\t2021-04-19\\t2021-05-19\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00991471\\tThe Effect of an Physician-Nurse Supplementary Triage Assistance Team on Emergency Department Patient Wait Times\\tMDRNSTAT\\tCOMPLETED\\tEmergencies\\tBEHAVIORAL: Interaction with MDRN STAT|BEHAVIORAL: No MDRNSTAT\\tSunnybrook Health Sciences Centre\\t\\t6300.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH\\t2009-09\\t2010-02\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05702671\\tKenota 1 CWS Method Comparison Validation Study\\t\\tCOMPLETED\\tAllergy|Immunoglobulin E-Mediated Allergic Disorder\\tDIAGNOSTIC_TEST: Total Immunoglobulin E\",\" Obtained From Fingerstick Sample\\tKenota Inc.\\t\\t411.0\\tINDUSTRY\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2023-01-27\\t2023-04-07\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02069171\\tCross-sectional and Questionnaire Study for Leg Lymphedema\\t\\tCOMPLETED\\tGynecologic Cancer\\t\\tNational Cancer Center\",\" Korea\\t\\t333.0\\tOTHER_GOV\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2012-06\\t2012-11\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00474071\\tOptimum Dose of Remifentanil for Intubation in Small Children\\t\\tCOMPLETED\\tEndotracheal Intubation\\tDRUG: Remifentanil\\tUniversity of British Columbia\\t\\t60.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: TREATMENT\\t2007-03\\t2008-04\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02022371\\tProstate Cancer Genomic Heterogeneity\\tPROGENY\\tCOMPLETED\\tPROSTATE CANCER\\tPROCEDURE: Targeted biopsies of the prostate\\tUniversity College London Hospitals\\t\\t50.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC\\t2014-09\\t2016-06\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04585971\\tA Study on Hemodynamic Relationship Including Cerebral Blood Flow Using Phase Contrast and Signal Intensity Gradient of Brain Magnetic Resonance Imaging\",\" and Carotid Doppler Ultrasound\\t\\tUNKNOWN\\tCerebral Blood Flow\\tDIAGNOSTIC_TEST: Signal intensity gradient\\tChonbuk National University Hospital\\tMedi Image\",\" Inc\\t30.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2020-09-03\\t2021-01-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05473871\\tEnhancing Capacity in Churches to Implement PA Programs\\t\\tRECRUITING\\tCardiovascular Diseases\\tBEHAVIORAL: Faith in Action|BEHAVIORAL: Faith in Action+|BEHAVIORAL: Faith in Action++\\tSan Diego State University\\tWashington University School of Medicine|University of California\", Berkeley|University of California,\" San Diego\\t812.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION\\t2022-11-15\\t2026-10-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01523171\\tPhase II\", Open Label,\" Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib\\tJAKARTA2\\tCOMPLETED\\tHematopoietic Neoplasm\\tDRUG: SAR302503\\tSanofi\\t\\t97.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2012-04\\t2014-04\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00000571\\tTrial of Inspiratory Muscle Rest and Exercise in Chronic Obstructive Lung Disease\\t\\tCOMPLETED\\tLung Diseases|Lung Diseases\",\" Obstructive|Chronic Obstructive Pulmonary Disease\\tDEVICE: ventilators\",\" negative pressure\\tMcGill University\\tNational Heart\", Lung,\" and Blood Institute (NHLBI)\\t\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: TREATMENT\\t1986-02\\t\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01053871\\tPropofol Versus Midazolam With Fentanyl for EGD Endomicroscopy\\t\\tCOMPLETED\\tGastritis|Functional Dyspepsia\\tDRUG: propofol|DRUG: midazolam with fentanyl\\tShandong University\\t\\t104.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT\",\" INVESTIGATOR)|Primary Purpose: \\t2010-01\\t2010-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02370771\\tProteomic Analysis in Sera From Patients With Erosive Hand Osteoarthritis\\tPASEO\\tCOMPLETED\\tErosive Hand Osteoarthritis\\tPROCEDURE: Biological sampling|DEVICE: Radiographic evaluation\\tUniversity Hospital\",\" Rouen\\t\\t32.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC\\t2015-06-09\\t2019-11-17\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05974371\\tEpisodic Memory Integration and Interference\\t\\tNOT_YET_RECRUITING\\tEpisodic Memory\\tOTHER: emotional context similarity\\tBoston College\\t\\t150.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE\\t2024-08\\t2027-08\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03713671\\tGait and Balance Parameters Before and After Parathyroidectomy in Patients With Primary Hyperparathyroidism\\t\\tCOMPLETED\\tPrimary Hyperparathyroidism\\tDIAGNOSTIC_TEST: gait analysis\\tRecep Tayyip Erdogan University Training and Research Hospital\\tHacettepe University|Ankara Education and Research Hospital\\t40.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING\\t2021-10-17\\t2023-08-27\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02645071\\tBrief Program in Reducing Sedentary Behavior and Promoting Physical Exercise\\t\\tCOMPLETED\\tPhysical Activity\\tBEHAVIORAL: Physical Activity\\tThe University of Hong Kong\\tHong Kong Jockey Club Charities Trust\\t141.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION\\t2015-07\\t2017-07\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04004871\\tInduction Chemotherapy With Nab-paclitaxel\",\" Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma\\t\\tUNKNOWN\\tNasopharyngeal Carcinoma|Nasopharyngeal Cancer|Nasopharynx Cancer\\tDRUG: Nab-paclitaxel\",\" Cisplatin and Fluorouracil|RADIATION: concurrent chemoradiotherapy\\tGuangxi Medical University\\tSecond Affiliated Hospital of Guangxi Medical University|Guilin Medical University\",\" China|Liuzhou Workers Hospital|Wuzhou Red Cross Hospital\\t60.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2019-07-05\\t2022-06-30\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05953571\\tLaparoscopic Assisted Dismembered Pyeloplasty Versus Open Pyeloplasty in (UPJO) With Poorly Function Kidney in Pediatrics\\t\\tCOMPLETED\\tUretro-pelvic Junction Obstruction|Poorly Function Kidney\\tPROCEDURE: Dismembered Pyeloplasty\\tAl-Azhar University\\tUniversity Hospital Fattouma Bourguiba\\t65.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2022-01-08\\t2023-06-30\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02570971\\tMannitol Versus Supportive Care in Ciguatera Fish Poisoning\\t\\tUNKNOWN\\tCiguatoxin\\tDRUG: Mannitol\\tUniversity of South Florida\\tFlorida Poison Control Center\\t200.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" INVESTIGATOR)|Primary Purpose: TREATMENT\\t2015-10\\t\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03987971\\tAcupuncture on GB26 to Treat Chronic Low Back Pain\\t\\tUNKNOWN\\tChronic Low-back Pain\\tOTHER: acupuncture\\tWenzhou Medical University\\tQingtian People\\'s hospital\\t114.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2020-01\\t2021-07\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01425671\\tNeural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States\\t\\tACTIVE_NOT_RECRUITING\\tSchizophrenia|Schizoaffective Disorder|Schizophreniform Disorder\\t\\tUniversity of Maryland\",\" Baltimore\\tNational Institute of Mental Health (NIMH)\\t800.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2010-11-30\\t2024-06\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04962971\\tComparative Effect of 3 Different Cranberry Extracts on Cystitis Related Urinary Comfort in Women\\t\\tCOMPLETED\\tRecurrent Cystitis\\tDIETARY_SUPPLEMENT: X|DIETARY_SUPPLEMENT: Y|DIETARY_SUPPLEMENT: Z\\tCEN Biotech\\tNexira|CEN Nutriment\\t216.0\\tINDUSTRY\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2020-09-01\\t2022-02-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02827071\\tOcular Imaging Study Using Advanced OCT\\t\\tUNKNOWN\\tRetinal Vascular Disorder|Macular Degeneration\\t\\tUniversity of California\",\" Los Angeles\\t\\t1000.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2016-07\\t\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04236271\\tTELEsurveillance of Patients in PostopErative Bridge surgeryAge CoronairE\\tTELE-PEACE\\tCOMPLETED\\tCoronary Artery Bypass\\tDEVICE: connected objects\\tAssistance Publique - Hôpitaux de Paris\\tGFI\\t33.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER\\t2020-03-13\\t2022-12-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01780571\\tCPAP/PSV Preoxygenation in Obese Patients\\t\\tCOMPLETED\\tObesity|Anaesthesia\\tPROCEDURE: CPAP 5 cm H2O + PSV 5 cm H2O\\tKarolinska Institutet\\t\\t44.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION\\t2009-05\\t2012-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05078671\\tPharmacokinetic Boosting of Olaparib to Improve Exposure\",\" Tolerance and Cost-effectiveness\\tPROACTIVE\\tRECRUITING\\tCancer\\tDRUG: Olaparib|DRUG: Cobicistat\\tRadboud University Medical Center\\t\\t160.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2021-12-15\\t2025-12-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02529371\\tPre-Marketing Feasibility Evaluation of the UriCap-RM - Urine Collection in Hospitalized Male Patients\\t\\tUNKNOWN\\tUrinary Incontinence\\tDEVICE: UriCap-RM\\tG.R. Dome Medical Ltd.\\t\\t30.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE\\t2015-09\\t2015-10\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02309671\\tA Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment\\t\\tCOMPLETED\\tInfertility\\tDRUG: FE 999049|DRUG: follitropin beta\\tFerring Pharmaceuticals\\t\\t159.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2014-12\\t2016-09\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03876171\\tCulturally Modified Family Based Therapy for Haitian Youth in South Florida\\t\\tCOMPLETED\\tProblem Behavior\\tBEHAVIORAL: Haitian youth and family intervention study: family functioning|BEHAVIORAL: Haitian youth intervention study: youth psychoeducational|BEHAVIORAL: Haitian family intervention study: family psychoeducational|BEHAVIORAL: Diversion Programs\\tUniversity of Miami\\tNational Institute on Drug Abuse (NIDA)\\t44.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT\\t2019-04-01\\t2022-12-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05031871\\tPharmacokinetics of HR17031 Injection in Healthy Subjects\\t\\tCOMPLETED\\tType 2 Diabetes Mellitus\\tDRUG: HR17031 injection ；INS068 injection；SHR20004 injection|DRUG: HR17031 injection ；INS068 injection；SHR20004 injection|DRUG: HR17031 injection ；INS068 injection；SHR20004 injection|DRUG: HR17031 injection ；INS068 injection；SHR20004 injection\\tJiangsu HengRui Medicine Co.\",\" Ltd.\\t\\t24.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT\\t2021-09-02\\t2021-11-19\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04769271\\tIntra-pocket Application of Tea Tree Oil Gel in the Treatment of Stage-2 Periodontitis\\t\\tCOMPLETED\\tPeriodontitis\\tPROCEDURE: Scaling and Root Planing|DRUG: Scaling and Root Planing with tea tree oil\\tAlexandria University\\t\\t30.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2019-11-10\\t2020-08-25\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT06044571\\tOptimizing Telehealth-delivery of a Weight Loss Intervention in Older Adults\\t\\tNOT_YET_RECRUITING\\tObesity|Multiple Chronic Conditions\\tOTHER: Prescriptive|BEHAVIORAL: Behavioral\\tUniversity of North Carolina\",\" Chapel Hill\\tNational Institute on Aging (NIA)\\t180.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT\",\" CARE_PROVIDER)|Primary Purpose: TREATMENT\\t2024-03-01\\t2027-09-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01889771\\tA Cost-effectiveness Study of Nicotine Patches Distributed Through a Quitline\\t\\tCOMPLETED\\tSmoking Cessation\\tDRUG: Nicotine Patch\\tUniversity of Colorado\",\" Denver\\t\\t1495.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH\\t2010-03\\t2012-03\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03077971\\tEffectiveness of Acceptance and Commitment Therapy Self-Help for Carers of People With Multiple Sclerosis\\t\\tUNKNOWN\\tCarer Stress Syndrome\\tBEHAVIORAL: ACT Self-Help|BEHAVIORAL: ACT Self-Help with Telephone Support\\tUniversity of Nottingham\\t\\t24.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE\\t2016-12-01\\t2018-06\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT02912871\\tSubthalamotomy by ExAblate Transcranial System to Treat Motor Features of Parkinson\\'s Disease\\t\\tCOMPLETED\\tParkinson\\'s Disease\\tOTHER: MRIgHIFU unilateral subthalamotomy\\tFundación de investigación HM\\tInsightech\\t10.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2016-04\\t2017-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03548571\\tDendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy\\tDEN-STEM\\tACTIVE_NOT_RECRUITING\\tGlioblastoma\\tBIOLOGICAL: Dendritic cell immunization|DRUG: Adjuvant temozolomide\\tOslo University Hospital\\t\\t60.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2018-04-26\\t2025-05-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01449071\\tStudy Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)\\t\\tCOMPLETED\\tSystemic Lupus Erythematosus\\tBIOLOGICAL: Placebo|BIOLOGICAL: Epratuzumab 400 mg|BIOLOGICAL: Epratuzumab 1200 mg|BIOLOGICAL: Epratuzumab 100 mg|BIOLOGICAL: Epratuzumab 600 mg\\tUCB Pharma\\t\\t20.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2011-10\\t2013-03\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT03530371\\tIntranasal Dexmedetomidine for Sedated Hearing Testing\\t\\tCOMPLETED\\tAuditory Brainstem Response\\tDRUG: Dexmedetomidine Hydrochloride\\tFondation Lenval\\t\\t60.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC\\t2019-05-02\\t2021-12-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05921071\\tDo Patients Who Received Tranexamic Acid in Vaginal Hysterectomy Loose Les Blood\",\" Comparing to Patients Who Did Not?\\t\\tRECRUITING\\tVaginal Hysterectomy\\tDRUG: Tranexamic acid|DRUG: Placebo\\tWolfson Medical Center\\t\\t150.0\\tOTHER_GOV\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT\", CARE_PROVIDER,\" OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE\\t2023-01-22\\t2025-01-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04974671\\tTrial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma\\t\\tRECRUITING\\tRenal Cell Carcinoma|Metastatic Renal Cell Carcinoma|Oligoprogressive|Progression\\tRADIATION: Stereotactic Body Radiation Therapy\\tYale University\\t\\t30.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2022-08-08\\t2027-04-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00080171\\tOsteoarthritis Initiative (OAI): A Knee Health Study\\t\\tCOMPLETED\\tOsteoarthritis|Knee Osteoarthritis\\t\\tNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)\\tGlaxoSmithKline|Merck Sharp & Dohme LLC|Novartis|Pfizer\\t4796.0\\tNIH\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2004-02\\t2015-10\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00368771\\tA Six-month Study to Compare Outcome Differences and Visceral Response ... Irritable Bowel Syndrome\\t\\tCOMPLETED\\tIrritable Bowel Syndrome\\tBEHAVIORAL: IBS Stress Management|BEHAVIORAL: IBS Symptom Management|BEHAVIORAL: IBS Educational Training\\tUniversity of California\",\" Los Angeles\\tNational Institute of Nursing Research (NINR)\\t163.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT\\t2002-07\\t2010-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04979871\\tSARS-CoV-2 Antibodies and Virus Neutralisation in a Cohort Vaccinted Against COVID-19\\tDER-CoV2-001\\tCOMPLETED\\tVaccine Reaction\\tPROCEDURE: Venous bleeding\\tUniversity of Zurich\\t\\t50.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2021-07-22\\t2021-12-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04097171\\tThe Effect of Diet Composition on Performance\", Expenditure, Blood Lipids,\" and Appetite Hormones in Highly Trained Cyclists\\tDCAP\\tCOMPLETED\\tEndurance Cycling Performance\\tOTHER: Diet\\tTexas Christian University\\t\\t34.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE\\t2019-11-11\\t2020-03-30\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT06199271\\tNeoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma\\t\\tNOT_YET_RECRUITING\\tHead and Neck Squamous Cell Carcinoma\\tDRUG: Adebrelimab and dalpiciclib\\tZhongzheng Xiang\\t\\t30.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2024-01-31\\t2026-12-31\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04032171\\tStudy of Evobrutinib in Participants With RMS\\t\\tTERMINATED\\tRelapsing-remitting Multiple Sclerosis\\tDRUG: Evobrutinib|DRUG: Avonex®|DRUG: Avonex® matched Placebo|DRUG: Evobrutinib matched Placebo\\tEMD Serono Research & Development Institute\",\" Inc.\\tMerck KGaA\", Darmstadt,\" Germany\\t1.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2019-09-10\\t2020-05-20\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05674071\\tApplying an Osteopathic Intervention to Improve Mental Health Symptoms: a Mixed-methods Feasibility Study Protocol.\\t\\tCOMPLETED\\tMental Health Issue\\tBEHAVIORAL: Articulation/HVT|BEHAVIORAL: Soft-tissue massage|BEHAVIORAL: Craniosacral techniques|BEHAVIORAL: Combination of the three interventions: HVT\",\" soft-tissue and craniosacral techniques\\tSwansea University\\tOsteopathic Foundation|University College of Osteopathy\\t32.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2022-12-20\\t2023-08-01\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT00858871\\tFirst Line Hepato Cellular Carcinoma (HCC)\\tBRISK FL\\tCOMPLETED\\tHepato Cellular Carcinoma (HCC)\\tDRUG: Brivanib|DRUG: Placebo|DRUG: Sorafenib|DRUG: Placebo\\tBristol-Myers Squibb\\t\\t1714.0\\tINDUSTRY\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT\", CARE_PROVIDER, INVESTIGATOR,\" OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2009-05\\t2013-09\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01776671\\tOnce Daily Gabapentin in the Treatment of Post Amputation Pain\\t\\tUNKNOWN\\tPain|Quality of Life\\tDRUG: Gralise\\tChicago Anesthesia Pain Specialists\\t\\t16.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2013-02\\t2018-12\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01363271\\tCost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients\\t\\tCOMPLETED\\tComplicated Skin and Structure Infection|Nosocomial Pneumonia\\tDRUG: Linezolid|DRUG: Vancomycin|DRUG: Linezolid|DRUG: Vancomycin\\tPfizer\\tUniversity of Maryland|Lodise & Lodise\",\" LLC\\t7260.0\\tINDUSTRY\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2011-05\\t2012-05\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT01282671\\tEffects of Deep Breathing Exercises Two Months After Cardiac Surgery\\t\\tCOMPLETED\\tCABG|Valve Surgery\\tOTHER: Breathing exercises\\tUppsala University\\tThe Swedish Research Council|Örebro County Council\\t357.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\t2007-09\\t2012-08\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05683171\\tA Phase 1/2\",\" Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma\\t\\tRECRUITING\\tLymphoma\\tDRUG: Rituximab|DRUG: Lenalidomide|DRUG: Valemetostat\\tM.D. Anderson Cancer Center\\tDaiichi Sankyo\\t60.0\\tOTHER\\tINTERVENTIONAL\\tAllocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT\\t2023-05-19\\t2027-09-30\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT05334771\\tEarly Detection of Endolymphatic Hydrops in Hypothyroid Patients\\t\\tNOT_YET_RECRUITING\\tHypothyroidism\\tDEVICE: Dual band pure tune audiometer\\tAssiut University\\t\\t50.0\\tOTHER\\tOBSERVATIONAL\\tObservational Model: |Time Perspective: p\\t2022-09\\t2025-04\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,\\r\\n\"NCT04718571\\tAn Ecological Analysis of Nontuberculous Mycobacteria in the Geneva Area (2015-2020)\\t\\tCOMPLETED\\tEcology of Nontubercuous Mycobacteria|Geneva Area\\t\\tUniversity Hospital\",\" Geneva\\t\\t231.0\\tOTHER\\tOBSERVATI'"
      ]
     },
     "execution_count": 1,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "fileroot = \"clinicaltrial_2023\"\n",
    "pharma = \"pharma\"\n",
    "\n",
    "dbutils.fs.head(\"/FileStore/tables/\" + fileroot + \".csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "6485a6fa-af5a-4ed6-ac30-71072abcfb95",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+------------+--------------------+----------+------------------+--------------------+--------------------+--------------------+--------------------+----------+-----------+--------------+--------------------+----------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|         \"Id|         Study Title|   Acronym|            Status|          Conditions|       Interventions|             Sponsor|       Collaborators|Enrollment|Funder Type|          Type|        Study Design|     Start|Completion\",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,|\n+------------+--------------------+----------+------------------+--------------------+--------------------+--------------------+--------------------+----------+-----------+--------------+--------------------+----------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|\"NCT03630471|Effectiveness of ...|     PRIDE|         COMPLETED|Mental Health Iss...|BEHAVIORAL: PRIDE...|             Sangath|Harvard Medical S...|     250.0|      OTHER|INTERVENTIONAL|Allocation: RANDO...|2018-08-20|                                                                                                                                                                                                         2019-02-28\",,,,,,...|\n|\"NCT05992571|Oral Ketone Monoe...|          |        RECRUITING|Cerebrovascular F...|OTHER: Placebo|DI...| McMaster University|Alzheimer's Socie...|      30.0|      OTHER|INTERVENTIONAL|Allocation: RANDO...|2023-10-25|                                                                                                                                                                                                         2024-08\",,,,,,,,,...|\n|\"NCT00237471|Impact of Tight G...|          |        TERMINATED|Myocardial Infarc...|DRUG: Insulin (ti...|    Melbourne Health|National Health a...|      40.0|      OTHER|INTERVENTIONAL|Allocation: RANDO...|   2005-10|                                                                                                                                                                                                         2006-05\",,,,,,,,,...|\n|\"NCT03820271|New Prognostic Pr...| SUPERMELD|        RECRUITING|Decompensated Cir...|    OTHER: SuperMELD|Assistance Publiq...|                    |     500.0|      OTHER|INTERVENTIONAL|Allocation: NA|In...|2020-10-01|                                                                                                                                                                                                         2023-10-01\",,,,,,...|\n|\"NCT06229171|InTake Care: Deve...|InTakeCare|NOT_YET_RECRUITING|Hypertension|Trea...|OTHER: adherence ...|Istituto Auxologi...|Istituti Clinici ...|     206.0|      OTHER|INTERVENTIONAL|Allocation: RANDO...|2024-10-01|                                                                                                                                                                                                         2026-04-01\",,,,,,...|\n|\"NCT02945371|Tailored Inhibito...|       REV|         COMPLETED|Smoking|Alcohol D...|BEHAVIORAL: Perso...|University of Oregon|                    |     103.0|      OTHER|INTERVENTIONAL|Allocation: RANDO...|   2014-09|                                                                                                                                                                                                         2016-05\",,,,,,,,,...|\n|\"NCT01055171|Neuromodulation o...|          |         COMPLETED|Alcohol Dependenc...|DRUG: Propranolol...|Medical Universit...|National Institut...|      44.0|      OTHER|INTERVENTIONAL|Allocation: RANDO...|   2010-01|                                                                                                                                                                                                         2012-08\",,,,,,,,,...|\n|\"NCT01125371|Computerized Brie...|          |         COMPLETED|Alcohol; Harmful ...|BEHAVIORAL: Compu...|Johns Hopkins Uni...|National Institut...|     439.0|      OTHER|INTERVENTIONAL|Allocation: RANDO...|   2011-10|                                                                                                                                                                                                         2016-06-07\",,,,,,...|\n|\"NCT02554071|Manitoba Pharmaci...|          |         COMPLETED|   Smoking Cessation|OTHER: Pharmacist...|University of Man...|Govenment of Mani...|     119.0|      OTHER|INTERVENTIONAL|Allocation: NA|In...|   2014-01|                                                                                                                                                                                                         2014-11\",,,,,,,,,...|\n|\"NCT01772771|Molecular Testing...|          |        RECRUITING|Glioma|Hematopoie...|PROCEDURE: Biospe...|M.D. Anderson Can...|National Cancer I...|   12000.0|      OTHER| OBSERVATIONAL|Observational Mod...|2012-03-01|                                                                                                                                                                                                         2033-03-01\",,,,,,...|\n|\"NCT02633371|A Pilot Study Exp...|          |         COMPLETED|       Hyperhidrosis|DRUG: Oxybutynin ...|University of Col...|Society for Pedia...|      10.0|      OTHER|INTERVENTIONAL|Allocation: NA|In...|   2016-02|                                                                                                                                                                                                         2017-05\",,,,,,,,,...|\n|\"NCT03400371|Biology of Juveni...|   BIOJUME|        RECRUITING|Juvenile Myocloni...|OTHER: Blood draw...|King's College Lo...|King's College Ho...|    1000.0|      OTHER| OBSERVATIONAL|Observational Mod...|2017-07-13|                                                                                                                                                                                                         2026-06-30\",,,,,,...|\n|\"NCT00120471|Safety and Blood ...|          |         COMPLETED|      HIV Infections|DRUG: Tenofovir d...|National Institut...|Eunice Kennedy Sh...|     122.0|        NIH|INTERVENTIONAL|Allocation: RANDO...|   2006-11|                                                                                                                                                                                                         2011-12\",,,,,,,,,...|\n|\"NCT04784871|Promoting Wellbei...|    5WaysA|         COMPLETED|Wellbeing|Health ...|BEHAVIORAL: 5ways...|  University of Oslo|Norwegian Institu...|     970.0|      OTHER|INTERVENTIONAL|Allocation: RANDO...|2021-03-04|                                                                                                                                                                                                         2023-02-24\",,,,,,...|\n|\"NCT02383771|Reversal of the A...|  REVERSAL|         COMPLETED|Coronary Artery D...|DRUG: Ticagrelor|...|The First Affilia...|National Natural ...|      64.0|      OTHER|INTERVENTIONAL|Allocation: RANDO...|   2015-03|                                                                                                                                                                                                         2016-12\",,,,,,,,,...|\n|\"NCT03269071|Neural Stem Cell ...|     STEMS|         COMPLETED|Progressive Multi...|DRUG: human fetal...|  IRCCS San Raffaele|Fondazione Italia...|       4.0|      OTHER|INTERVENTIONAL|Allocation: NON_R...|2017-05-17|                                                                                                                                                                                                         2021-07-31\",,,,,,...|\n|\"NCT01659671|RCT of the Effect...|     SKUP3|         COMPLETED|Obstructive Sleep...|PROCEDURE: Uvulop...|Karolinska Univer...|Karolinska Instit...|      65.0|      OTHER|INTERVENTIONAL|Allocation: RANDO...|   2007-06|                                                                                                                                                                                                         2014-05\",,,,,,,,,...|\n|\"NCT04765371|Comparison Betwee...|  COPreDex|         COMPLETED|Coronavirus Infec...|DRUG: DEXAMETHASO...|        Hôpital NOVO|                    |      89.0|      OTHER|INTERVENTIONAL|Allocation: RANDO...|2021-03-03|                                                                                                                                                                                                         2022-05-13\",,,,,,...|\n|\"NCT02830971|Developing a Stan...|          |         COMPLETED|Registered Nurses...|PROCEDURE: Doing ...|Baqiyatallah Medi...|Shahid Beheshti U...|      60.0|      OTHER|INTERVENTIONAL|Allocation: NA|In...|   2016-07|                                                                                                                                                                                                         2021-04-12\",,,,,,...|\n|\"NCT00416871|Interleukin-2 and...|          |         COMPLETED|       Kidney Cancer|BIOLOGICAL: aldes...|  Centre Leon Berard|                    |     220.0|      OTHER|INTERVENTIONAL|Allocation: RANDO...|          |                                                                                                                                                                                                         2006-02\",,,,,,,,,...|\n+------------+--------------------+----------+------------------+--------------------+--------------------+--------------------+--------------------+----------+-----------+--------------+--------------------+----------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\nonly showing top 20 rows\n\n"
     ]
    }
   ],
   "source": [
    "from pyspark.sql.functions import monotonically_increasing_id\n",
    "\n",
    "# A dictionary to store different delimiters for each clinical trial file\n",
    "delimiter_selector = {\n",
    "    \"clinicaltrial_2023\": \"\\t\",\n",
    "    \"clinicaltrial_2021\": \"|\",\n",
    "    \"clinicaltrial_2020\": \"|\",\n",
    "    \"pharma\": \",\"\n",
    "}\n",
    "\n",
    "# Function to create a DataFrame\n",
    "def create_dataframe(clinicaltrial_2023):\n",
    "    # If the clinical trial is 2023\n",
    "    if clinicaltrial_2023 == \"clinicaltrial_2023\":\n",
    "        # Read the data file as an RDD, split rows by delimiter, and handle column mismatches\n",
    "        rdd = sc.textFile(f\"/FileStore/tables/{clinicaltrial_2023}.csv\").map(lambda row: row.split(delimiter_selector[clinicaltrial_2023]))\n",
    "        head = rdd.first() # Extract header\n",
    "        # Ensure each row has the same number of columns as the header\n",
    "        rdd = rdd.map(lambda row: row + [\" \" for i in range(len(head) - len(row))] if len(row) < len(head) else row )\n",
    "        # Convert RDD to DataFrame\n",
    "        df = rdd.toDF()\n",
    "        first = df.first() # Extract first row\n",
    "        # Rename columns with \"_<index>\" to their corresponding names from the first row\n",
    "        for col in range(0, len(list(first))):\n",
    "           df = df.withColumnRenamed(f\"_{col + 1}\", list(first)[col])\n",
    "        # Add an index column to the DataFrame\n",
    "        df = df.withColumn('index', monotonically_increasing_id())\n",
    "        # Filter out the first row (header) and drop the index column\n",
    "        return df.filter(~df.index.isin([0])).drop('index')\n",
    "    # For other clinical trial years, assuming CSV files with headers\n",
    "    else:\n",
    "        # Read the CSV file directly into a DataFrame using Spark SQL\n",
    "        return spark.read.csv(f\"/FileStore/tables/{clinicaltrial_2023}.csv\", sep=delimiter_selector[clinicaltrial_2023], header=True)\n",
    "\n",
    "# Call the function to create the DataFrame for the specified clinical trial\n",
    "clinical_dataframe = create_dataframe(\"clinicaltrial_2023\")\n",
    "\n",
    "# Show the first 20 rows of the DataFrame\n",
    "clinical_dataframe.show(20)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "4f7d7f8f-596e-4585-a68c-5fd8fe91c56a",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "483422"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# QUESTION 1: NUMBER OF STUDIES IN THE DATASET\n",
    "\n",
    "# Count the number of distinct rows in the DataFrame, effectively counting the number of unique rows.\n",
    "clinical_dataframe.distinct().count()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "52fa30cb-0c29-4274-90de-61ac6de148d3",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+---------------+------+\n|           Type| count|\n+---------------+------+\n| INTERVENTIONAL|371382|\n|  OBSERVATIONAL|110221|\n|EXPANDED_ACCESS|   928|\n+---------------+------+\nonly showing top 3 rows\n\n"
     ]
    }
   ],
   "source": [
    "# QUESTION TWO: ALL TYPES OF TRIALS & THEIR FREQUENCY\n",
    "clinical_dataframe.groupBy('Type').count().orderBy('count', ascending=False).show(3)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "5c1fbb0a-785f-4ec3-b80a-4c21306e304f",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+---------------+-----+\n|Conditions     |count|\n+---------------+-----+\n|Healthy        |7997 |\n|Breast Cancer  |4556 |\n|Prostate Cancer|2650 |\n|Asthma         |2309 |\n|Obesity        |2284 |\n+---------------+-----+\nonly showing top 5 rows\n\n"
     ]
    }
   ],
   "source": [
    "# QUESTION 3: TOP 5 CONDITIONS WITH THEIR FREQUENCIES\n",
    "\n",
    "from pyspark.sql.functions import split, explode, trim, col\n",
    "\n",
    "# Define delimiter for the Conditions column based on the clinical trial data\n",
    "conditions_delimiter = {\n",
    "    \"clinicaltrial_2023\": \"\\t\",\n",
    "    \"clinicaltrial_2021\": \",\",\n",
    "    \"clinicaltrial_2020\": \",\",\n",
    "}\n",
    "\n",
    "# Split the Conditions column based on the delimiter for the specific clinical trial data\n",
    "split_conditions_df = clinical_dataframe \\\n",
    "    .withColumn('Conditions', explode(split(trim(col('Conditions')), conditions_delimiter[fileroot])))\n",
    "\n",
    "# Group by Conditions, count occurrences, and filter out empty values\n",
    "result_df = split_conditions_df \\\n",
    "    .groupBy('Conditions') \\\n",
    "    .count() \\\n",
    "    .orderBy('count', ascending=False) \\\n",
    "    .filter(\"Conditions != ''\")\n",
    "\n",
    "# Show top 5 results\n",
    "result_df.show(5, truncate=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "c906a565-be24-4edd-ab7a-1b14c55340d4",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+--------------------+-----+\n|             Sponsor|count|\n+--------------------+-----+\n|National Cancer I...| 3410|\n|   Assiut University| 3335|\n|    Cairo University| 3023|\n|Assistance Publiq...| 2951|\n|         Mayo Clinic| 2766|\n|M.D. Anderson Can...| 2702|\n|Novartis Pharmace...| 2393|\n|National Institut...| 2340|\n|Massachusetts Gen...| 2263|\n|National Taiwan U...| 2181|\n+--------------------+-----+\nonly showing top 10 rows\n\n"
     ]
    }
   ],
   "source": [
    "# QUESTION 4: RETRIEVE THE TOP 10 SPONSORS THAT ARE NOT PHARMACEUTICAL COMPANIES  \n",
    "pharma_list = create_dataframe(pharma).select(\"Parent_Company\").rdd.flatMap(lambda x: x).collect()\n",
    "clinical_sponsor_dataframe = clinical_dataframe.select(\"Sponsor\")\n",
    "\n",
    "non_pharma_sponsors = clinical_sponsor_dataframe.groupBy(\"Sponsor\").count().orderBy(\"count\", ascending=False).filter(~clinical_sponsor_dataframe.Sponsor.isin(pharma_list)).show(10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "7e678603-393f-4101-9e5a-5e4702957d1a",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+---------+-----+\n|    Month|count|\n+---------+-----+\n|  January| 1494|\n| February| 1272|\n|    March| 1552|\n|    April| 1324|\n|      May| 1415|\n|     June| 1619|\n|     July| 1360|\n|   August| 1230|\n|September| 1152|\n|  October| 1058|\n| November|  909|\n| December| 1082|\n+---------+-----+\n\n"
     ]
    }
   ],
   "source": [
    "# Question 5:PLOTTING THE NUMBER OF COMPLETED STUDIES EACH MONTH IN A GIVEN YEAR\n",
    "\n",
    "from pyspark.sql.functions import split, regexp_replace, when\n",
    "\n",
    "# Rename columns to remove any leading or trailing commas and quotes\n",
    "for col in clinical_dataframe.columns:\n",
    "    clinical_dataframe = clinical_dataframe.withColumnRenamed(col, col.strip(\",\").strip('\"'))\n",
    "\n",
    "# Define a dictionary to map numerical month values to month names\n",
    "month_names = {\n",
    "    \"01\": \"January\", \"02\": \"February\", \"03\": \"March\", \"04\": \"April\", \"05\": \"May\", \"06\": \"June\",\n",
    "    \"07\": \"July\", \"08\": \"August\", \"09\": \"September\", \"10\": \"October\", \"11\": \"November\", \"12\": \"December\"\n",
    "}\n",
    "\n",
    "# Extract year and month from the 'Completion' column and clean month format\n",
    "completed_cd = clinical_dataframe \\\n",
    "    .withColumn('Year', split('Completion', \"-\")[0]) \\\n",
    "    .withColumn('Month', split('Completion', \"-\")[1]) \\\n",
    "    .withColumn('Month', regexp_replace(\"Month\", \",\", \"\")) \\\n",
    "    .withColumn('Month', regexp_replace(\"Month\", '\"', \"\")) \\\n",
    "    .filter(clinical_dataframe.Status.isin([\"COMPLETED\"])) \\\n",
    "    .select(\"Month\", \"Year\", \"Status\")\n",
    "\n",
    "# Filter for the year 2023 and group by month\n",
    "completed_cd_2023 = completed_cd.filter(completed_cd.Year.isin([\"2023\"])) \\\n",
    "    .groupBy(\"Month\").count().orderBy(\"Month\", ascending=True)\n",
    "\n",
    "# Map numerical month values to month names\n",
    "completed_cd_2023 = completed_cd_2023.withColumn(\"Month\", \n",
    "                                                 when(completed_cd_2023[\"Month\"] == \"01\", \"January\")\n",
    "                                                 .when(completed_cd_2023[\"Month\"] == \"02\", \"February\")\n",
    "                                                 .when(completed_cd_2023[\"Month\"] == \"03\", \"March\")\n",
    "                                                 .when(completed_cd_2023[\"Month\"] == \"04\", \"April\")\n",
    "                                                 .when(completed_cd_2023[\"Month\"] == \"05\", \"May\")\n",
    "                                                 .when(completed_cd_2023[\"Month\"] == \"06\", \"June\")\n",
    "                                                 .when(completed_cd_2023[\"Month\"] == \"07\", \"July\")\n",
    "                                                 .when(completed_cd_2023[\"Month\"] == \"08\", \"August\")\n",
    "                                                 .when(completed_cd_2023[\"Month\"] == \"09\", \"September\")\n",
    "                                                 .when(completed_cd_2023[\"Month\"] == \"10\", \"October\")\n",
    "                                                 .when(completed_cd_2023[\"Month\"] == \"11\", \"November\")\n",
    "                                                 .when(completed_cd_2023[\"Month\"] == \"12\", \"December\"))\n",
    "\n",
    "# Show the result\n",
    "completed_cd_2023.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "0c4d9aec-8bd3-4316-be9a-4a13d282cc94",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "display_data",
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "import pandas as pd\n",
    "\n",
    "# Assuming completed_cd_2023 is the DataFrame containing the result\n",
    "result_df = completed_cd_2023.toPandas()\n",
    "\n",
    "# Define a list of colors for each bar\n",
    "colors = ['skyblue', 'orange', 'green', 'red', 'purple', 'brown', 'pink', 'gray', 'olive', 'cyan', 'magenta', 'yellow']\n",
    "\n",
    "# Plotting the bar chart with different colors\n",
    "plt.figure(figsize=(10, 6))\n",
    "plt.bar(result_df['Month'], result_df['count'], color=colors)\n",
    "\n",
    "# Add title and labels\n",
    "plt.title('Number of Completed Studies in Each Month (2023)')\n",
    "plt.xlabel('Month')\n",
    "plt.ylabel('Number of Completed Studies')\n",
    "\n",
    "# Rotate x-axis labels for better readability\n",
    "plt.xticks(rotation=45)\n",
    "\n",
    "# Show plot\n",
    "plt.tight_layout()\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "08cf8e4f-e1f1-445c-8eba-d40b3ef195cf",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "# FURTHER ANALYSIS  "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "f8b953b2-4b36-4f7c-b1f4-17535313a387",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+--------------------+-----+\n|             Sponsor|count|\n+--------------------+-----+\n|     GlaxoSmithKline| 3482|\n|              Pfizer| 3045|\n|         AstraZeneca| 3024|\n|Boehringer Ingelheim| 2146|\n|              Sanofi| 1404|\n|Bristol-Myers Squibb| 1383|\n|               Amgen|  851|\n|              AbbVie|  728|\n|            Novartis|  697|\n|     Gilead Sciences|  625|\n+--------------------+-----+\n\n"
     ]
    }
   ],
   "source": [
    "# QUESTION 7: Companies that are pharmaceutical companies\n",
    "from pyspark.sql.functions import col\n",
    "\n",
    "# Retrieve the list of pharmaceutical companies\n",
    "pharma_list = create_dataframe(pharma).select(\"Parent_Company\").rdd.flatMap(lambda x: x).collect()\n",
    "\n",
    "# Filter out pharmaceutical companies from the clinical trial sponsors\n",
    "pharma_sponsors = clinical_dataframe.select(\"Sponsor\").groupBy(\"Sponsor\").count().filter(col(\"Sponsor\").isin(pharma_list)).orderBy(\"count\", ascending=False).limit(10)\n",
    "\n",
    "# Show the top 10 pharmaceutical sponsors\n",
    "pharma_sponsors.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "8bdcc473-3206-4d1a-b316-80c4beb20a19",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "application/vnd.databricks.v1+notebook": {
   "dashboards": [],
   "language": "python",
   "notebookMetadata": {
    "mostRecentlyExecutedCommandWithImplicitDF": {
     "commandId": 4283575042172322,
     "dataframes": [
      "_sqldf"
     ]
    },
    "pythonIndentUnit": 4
   },
   "notebookName": "Oluwadamilola_Kolawole_df",
   "widgets": {}
  }
 },
 "nbformat": 4,
 "nbformat_minor": 0
}
